EP 1237577 A2 20020911 - TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Title (en)
TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Title (de)
TRANSDERMALES PHOSPHODIESTERASE-HEMMER ENHALTENDES ARZNEIMITTEL ZUR BEHANDLUNG VON EREKTILER DYSFUNKTION
Title (fr)
ADMINISTRATION A TRAVERS LES MUQUEUSES D'INHIBITEURS DE LA PHOSPHODIESTERASE DANS LE TRAITEMENT DE LA DYSERECTION
Publication
Application
Priority
- US 0033372 W 20001208
- US 46709499 A 19991210
Abstract (en)
[origin: WO0141807A2] A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.
IPC 1-7
IPC 8 full level
A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 31/00 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/4015 (2006.01); A61K 31/4164 (2006.01); A61K 31/4166 (2006.01); A61K 31/426 (2006.01); A61K 31/437 (2006.01); A61K 31/4412 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/47 (2006.01); A61K 31/4704 (2006.01); A61K 31/4709 (2006.01); A61K 31/4745 (2006.01); A61K 31/485 (2006.01); A61K 31/496 (2006.01); A61K 31/50 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/505 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/522 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/549 (2006.01); A61K 31/5513 (2006.01); A61K 31/5517 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 15/10 (2006.01); A61P 25/02 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP US)
A61K 9/0031 (2013.01 - EP US); A61K 9/0034 (2013.01 - EP US); A61K 9/0056 (2013.01 - EP US); A61K 9/006 (2013.01 - EP US); A61K 31/00 (2013.01 - EP US); A61K 31/343 (2013.01 - EP US); A61K 31/381 (2013.01 - EP US); A61K 31/40 (2013.01 - EP US); A61K 31/4015 (2013.01 - EP US); A61K 31/4164 (2013.01 - EP US); A61K 31/4166 (2013.01 - EP US); A61K 31/426 (2013.01 - EP US); A61K 31/437 (2013.01 - EP US); A61K 31/4439 (2013.01 - EP US); A61K 31/444 (2013.01 - EP US); A61K 31/4704 (2013.01 - EP US); A61K 31/4709 (2013.01 - EP US); A61K 31/4745 (2013.01 - EP US); A61K 31/496 (2013.01 - EP US); A61K 31/50 (2013.01 - EP US); A61K 31/501 (2013.01 - EP US); A61K 31/502 (2013.01 - EP US); A61K 31/5025 (2013.01 - EP US); A61K 31/505 (2013.01 - EP US); A61K 31/519 (2013.01 - EP US); A61K 31/52 (2013.01 - EP US); A61K 31/522 (2013.01 - EP US); A61K 31/538 (2013.01 - EP US); A61K 31/549 (2013.01 - EP US); A61K 31/5513 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 9/00 (2017.12 - EP); A61P 15/10 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 0141807A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT
DOCDB simple family (publication)
WO 0141807 A2 20010614; WO 0141807 A3 20020214; AU 2256601 A 20010618; CA 2394060 A1 20010614; EP 1237577 A2 20020911; JP 2003516363 A 20030513; US 2002004498 A1 20020110; US 2003134861 A1 20030717; US 6548490 B1 20030415
DOCDB simple family (application)
US 0033372 W 20001208; AU 2256601 A 20001208; CA 2394060 A 20001208; EP 00986297 A 20001208; JP 2001543151 A 20001208; US 35119803 A 20030124; US 46709499 A 19991210; US 93841701 A 20010823